DANONE (BSN.DE) Stock Fundamental Analysis
Europe - FRA:BSN - FR0000120644 - Common Stock
74.64 EUR
-0.18 (-0.24%)
BSN gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 58 industry peers in the Food Products industry. BSN has a medium profitability rating, but doesn't score so well on its financial health evaluation. BSN is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year BSN was profitable.
BSN had a positive operating cash flow in the past year.
BSN had positive earnings in each of the past 5 years.
Each year in the past 5 years BSN had a positive operating cash flow.
1.2 Ratios
BSN has a Return On Assets (4.20%) which is in line with its industry peers.
BSN's Return On Equity of 11.59% is fine compared to the rest of the industry. BSN outperforms 64.41% of its industry peers.
The Return On Invested Capital of BSN (6.83%) is better than 62.71% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for BSN is in line with the industry average of 7.05%.
The 3 year average ROIC (6.38%) for BSN is below the current ROIC(6.83%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.2% | ||
| ROE | 11.59% | ||
| ROIC | 6.83% |
ROA(3y)2.83%
ROA(5y)3.44%
ROE(3y)7.34%
ROE(5y)9%
ROIC(3y)6.38%
ROIC(5y)6.21%
1.3 Margins
With a decent Profit Margin value of 6.72%, BSN is doing good in the industry, outperforming 71.19% of the companies in the same industry.
In the last couple of years the Profit Margin of BSN has remained more or less at the same level.
Looking at the Operating Margin, with a value of 13.25%, BSN is in the better half of the industry, outperforming 76.27% of the companies in the same industry.
BSN's Operating Margin has declined in the last couple of years.
The Gross Margin of BSN (50.47%) is better than 74.58% of its industry peers.
BSN's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 13.25% | ||
| PM (TTM) | 6.72% | ||
| GM | 50.47% |
OM growth 3Y-1.81%
OM growth 5Y-3.08%
PM growth 3Y-1.94%
PM growth 5Y-0.54%
GM growth 3Y1.56%
GM growth 5Y0.26%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so BSN is still creating some value.
The number of shares outstanding for BSN has been increased compared to 1 year ago.
BSN has less shares outstanding than it did 5 years ago.
Compared to 1 year ago, BSN has an improved debt to assets ratio.
2.2 Solvency
An Altman-Z score of 2.51 indicates that BSN is not a great score, but indicates only limited risk for bankruptcy at the moment.
With a Altman-Z score value of 2.51, BSN perfoms like the industry average, outperforming 59.32% of the companies in the same industry.
The Debt to FCF ratio of BSN is 5.07, which is a neutral value as it means it would take BSN, 5.07 years of fcf income to pay off all of its debts.
BSN has a Debt to FCF ratio of 5.07. This is in the better half of the industry: BSN outperforms 62.71% of its industry peers.
A Debt/Equity ratio of 0.83 indicates that BSN is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.83, BSN is not doing good in the industry: 66.10% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.83 | ||
| Debt/FCF | 5.07 | ||
| Altman-Z | 2.51 |
ROIC/WACC1.09
WACC6.25%
2.3 Liquidity
A Current Ratio of 0.95 indicates that BSN may have some problems paying its short term obligations.
BSN has a Current ratio of 0.95. This is in the lower half of the industry: BSN underperforms 76.27% of its industry peers.
A Quick Ratio of 0.78 indicates that BSN may have some problems paying its short term obligations.
With a Quick ratio value of 0.78, BSN perfoms like the industry average, outperforming 42.37% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.95 | ||
| Quick Ratio | 0.78 |
3. Growth
3.1 Past
BSN shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 4.47%.
The Earnings Per Share has been decreasing by -1.17% on average over the past years.
Looking at the last year, BSN shows a small growth in Revenue. The Revenue has grown by 0.54% in the last year.
BSN shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 1.60% yearly.
EPS 1Y (TTM)4.47%
EPS 3Y3.12%
EPS 5Y-1.17%
EPS Q2Q%6.11%
Revenue 1Y (TTM)0.54%
Revenue growth 3Y4.08%
Revenue growth 5Y1.6%
Sales Q2Q%-0.15%
3.2 Future
Based on estimates for the next years, BSN will show a small growth in Earnings Per Share. The EPS will grow by 5.54% on average per year.
The Revenue is expected to grow by 3.03% on average over the next years.
EPS Next Y7.14%
EPS Next 2Y6.65%
EPS Next 3Y7.05%
EPS Next 5Y5.54%
Revenue Next Year0.87%
Revenue Next 2Y1.88%
Revenue Next 3Y2.55%
Revenue Next 5Y3.03%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 19.96 indicates a rather expensive valuation of BSN.
The rest of the industry has a similar Price/Earnings ratio as BSN.
When comparing the Price/Earnings ratio of BSN to the average of the S&P500 Index (27.30), we can say BSN is valued slightly cheaper.
With a Price/Forward Earnings ratio of 18.08, BSN is valued on the expensive side.
BSN's Price/Forward Earnings ratio is in line with the industry average.
The average S&P500 Price/Forward Earnings ratio is at 22.73. BSN is valued slightly cheaper when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.96 | ||
| Fwd PE | 18.08 |
4.2 Price Multiples
The rest of the industry has a similar Enterprise Value to EBITDA ratio as BSN.
The rest of the industry has a similar Price/Free Cash Flow ratio as BSN.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 17.73 | ||
| EV/EBITDA | 10.73 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
BSN has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)2.79
PEG (5Y)N/A
EPS Next 2Y6.65%
EPS Next 3Y7.05%
5. Dividend
5.1 Amount
BSN has a Yearly Dividend Yield of 2.87%.
Compared to an average industry Dividend Yield of 3.27, BSN pays a bit more dividend than its industry peers.
Compared to an average S&P500 Dividend Yield of 2.38, BSN pays a bit more dividend than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.87% |
5.2 History
The dividend of BSN has a limited annual growth rate of 1.58%.
Dividend Growth(5Y)1.58%
Div Incr Years3
Div Non Decr Years4
5.3 Sustainability
74.99% of the earnings are spent on dividend by BSN. This is not a sustainable payout ratio.
BSN's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP74.99%
EPS Next 2Y6.65%
EPS Next 3Y7.05%
FRA:BSN (9/12/2025, 7:00:00 PM)
74.64
-0.18 (-0.24%)
Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupFood, Beverage & Tobacco
GICS IndustryFood Products
Earnings (Last)
Earnings (Next)
Inst Owners48.65%
Inst Owner ChangeN/A
Ins Owners0%
Ins Owner ChangeN/A
Market Cap50.86B
Analysts72.26
Price Target77.34 (3.62%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.87% |
Yearly Dividend2.1
Dividend Growth(5Y)1.58%
DP74.99%
Div Incr Years3
Div Non Decr Years4
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.13%
PT rev (3m)2.85%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-0.76%
EPS NY rev (3m)-0.76%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0.07%
Revenue NY rev (3m)-0.87%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.96 | ||
| Fwd PE | 18.08 | ||
| P/S | 1.86 | ||
| P/FCF | 17.73 | ||
| P/OCF | 13.22 | ||
| P/B | 3.21 | ||
| P/tB | N/A | ||
| EV/EBITDA | 10.73 |
EPS(TTM)3.74
EY5.01%
EPS(NY)4.13
Fwd EY5.53%
FCF(TTM)4.21
FCFY5.64%
OCF(TTM)5.64
OCFY7.56%
SpS40.15
BVpS23.28
TBVpS-9.5
PEG (NY)2.79
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.2% | ||
| ROE | 11.59% | ||
| ROCE | 12.02% | ||
| ROIC | 6.83% | ||
| ROICexc | 8.36% | ||
| ROICexgc | 50.58% | ||
| OM | 13.25% | ||
| PM (TTM) | 6.72% | ||
| GM | 50.47% | ||
| FCFM | 10.49% |
ROA(3y)2.83%
ROA(5y)3.44%
ROE(3y)7.34%
ROE(5y)9%
ROIC(3y)6.38%
ROIC(5y)6.21%
ROICexc(3y)7.67%
ROICexc(5y)7.39%
ROICexgc(3y)52.44%
ROICexgc(5y)45.6%
ROCE(3y)10.98%
ROCE(5y)10.58%
ROICexcg growth 3Y19.7%
ROICexcg growth 5Y13.36%
ROICexc growth 3Y4.65%
ROICexc growth 5Y1.26%
OM growth 3Y-1.81%
OM growth 5Y-3.08%
PM growth 3Y-1.94%
PM growth 5Y-0.54%
GM growth 3Y1.56%
GM growth 5Y0.26%
F-Score8
Asset Turnover0.63
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.83 | ||
| Debt/FCF | 5.07 | ||
| Debt/EBITDA | 2.71 | ||
| Cap/Depr | 77.72% | ||
| Cap/Sales | 3.57% | ||
| Interest Coverage | 23.53 | ||
| Cash Conversion | 78.8% | ||
| Profit Quality | 156.01% | ||
| Current Ratio | 0.95 | ||
| Quick Ratio | 0.78 | ||
| Altman-Z | 2.51 |
F-Score8
WACC6.25%
ROIC/WACC1.09
Cap/Depr(3y)59.49%
Cap/Depr(5y)65.43%
Cap/Sales(3y)3.2%
Cap/Sales(5y)3.59%
Profit Quality(3y)220.86%
Profit Quality(5y)178.79%
High Growth Momentum
Growth
EPS 1Y (TTM)4.47%
EPS 3Y3.12%
EPS 5Y-1.17%
EPS Q2Q%6.11%
EPS Next Y7.14%
EPS Next 2Y6.65%
EPS Next 3Y7.05%
EPS Next 5Y5.54%
Revenue 1Y (TTM)0.54%
Revenue growth 3Y4.08%
Revenue growth 5Y1.6%
Sales Q2Q%-0.15%
Revenue Next Year0.87%
Revenue Next 2Y1.88%
Revenue Next 3Y2.55%
Revenue Next 5Y3.03%
EBIT growth 1Y3.81%
EBIT growth 3Y2.2%
EBIT growth 5Y-1.53%
EBIT Next Year35.65%
EBIT Next 3Y14.25%
EBIT Next 5Y9.9%
FCF growth 1Y12.42%
FCF growth 3Y6.14%
FCF growth 5Y3.12%
OCF growth 1Y12.55%
OCF growth 3Y3.31%
OCF growth 5Y2.15%